Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
-EBI and support organisational change projects across EMBL. Develop, maintain, and constantly improve a range of internal communications channels such as EMBL-EBI’s intranet, Town Hall meetings
-
his/her node’s host university, while collaborating with a co-supervisor from a different Nordic EMBL node. As a NORPOD Fellow, you will develop a collaborative project under the supervision of two
-
Universities of Aarhus (Denmark), Helsinki (Finland), Oslo (Norway) and Umeå (Sweden) | Denmark, Maine | United States | 11 days ago
his/her node’s host university, while collaborating with a co-supervisor from a different Nordic EMBL node. As a NORPOD Fellow, you will develop a collaborative project under the supervision of two
-
About the team/job EMBL is Europe’s life sciences laboratory – an intergovernmental organisation with more than 80 independent research groups covering the spectrum of molecular biology. EMBL has
-
for monogenic immune diseases. We use high-throughput biology techniques to optimize, develop and understand the CRISPR-Cas9 system that forms the base of the platform, and develop and implement methods
-
NORPOD is a collaborative postdoctoral program of the Nordic EMBL Partnership for Molecular Medicine . The partnership is a network of four national research centers across the Nordics and the
-
biology techniques to optimize, develop and understand the CRISPR-Cas9 system that forms the base of the platform, and develop and implement methods to evaluate its safety in a clinical setting. We will use
-
Galej at the EMBL Grenoble, France. We are looking for a highly motivated and ambitious individual to join our team interested in the structure and function of RNA-protein complexes. Our group
-
editing platform that can be used to correct patient-specific mutations in ex vivo cell therapies for monogenic immune diseases. We use high-throughput biology techniques to optimize, develop and understand
-
a gene editing platform that can be used to correct patient-specific mutations in ex vivo cell therapies for monogenic immune diseases. We use high-throughput biology techniques to optimize, develop